David Gandara: “not so fast”

David Gandara, Director of Thoracic Oncology and Senior Advisor to the Director at University of California Davis Comprehensive Cancer Center (UCDCCC), shared a post by Vivek Subbiah on X/Twitter adding:

“Congratulations Vivek Subbiah on addressing unmet need to standardize criteria for liquid biopsy response. But as the saying goes, “not so fast”! Considering wide variability in assay methods and computational algorithms, first need to harmonize assays themselves.”

Quoting Vivek Subbiah’s post:

“Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST) – Annals of Oncology.
Thank you. Yes ! This is just the beginning of the conversation on using LB for response. We outline several issues that need to be addressed before recommending the implementation of ctDNA response criteria in daily clinical practice such as clinical, biological, and regulatory challenges and, most importantly, the need to standardize/harmonize detection methods and ways to define ctDNA response and/or progression for precision oncology.”

Read further.
Source: David Gandara/X and Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.